1231929-97-7
- Product Name：Abemaciclib
- Molecular Formula：C27H32F2N8
- Purity：99%
- Molecular Weight：506.601
Product Details:
CasNo： 1231929-97-7
Molecular Formula： C27H32F2N8
Quality Manufacturer Supply Best Quality Abemaciclib 1231929-97-7 Safe Transportation
- Molecular Formula:C27H32F2N8
- Molecular Weight:506.601
- Boiling Point:689.3±65.0 °C(Predicted)
- PKA:7.69±0.10(Predicted)
- PSA：75.00000
- Density:1.32±0.1 g/cm3(Predicted)
- LogP:4.88570
Abemaciclib(Cas 1231929-97-7) Usage
|
Description |
Abemaciclib, marketed under the brand name Verzenio™, is a medication developed by Eli Lilly and Company for the treatment of advanced or metastatic breast cancers. It is specifically used in the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. |
| Uses |
Advanced or Metastatic Breast Cancer: Abemaciclib has been approved in the USA for the treatment of HR+ HER2- advanced or metastatic breast cancer, both as a monotherapy and in combination with other therapies. a. In Combination with Fulvestrant: Used in women with disease progression following endocrine therapy. b. As Monotherapy: Administered in adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. Abemaciclib is also being investigated internationally for its potential efficacy in various other cancers beyond breast cancer. |
1231929-97-7 Relevant articles
A synthesis of abemaciclib utilizing a Leuckart-Wallach reaction
Takeshi Kotake &Masakazu Toi
, Expert Opinion on Pharmacotherapy Volume 19, 2018 - Issue 5
Another problem is that its contribution to overall survival (OS) has not been shown. And while two large the phase 3 study highlighted the anti-tumour effect of abemaciclib, the OS results are awaited. Furthermore, the effect on brain metastases is expected to be unique to abemaciclib as the response of brain metastasis in HR-positive breast cancer patients has been confirmed in a few cases with case collection still ongoing.
Sustainable synthesis of potential antitumor new derivatives of Abemaciclib and Fedratinib via C-N cross coupling reactions using Pd/Cu-free Co-catalyst
Khorsandi, Zahra,Keshavarzipour, Fariba,Varma, Rajender S.,Hajipour, Abdol R.,Sadeghi-Aliabadi, Hojjat
, (2021/11/24)
Herein, chitosan as an inexpensive, abun...
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
Silvia Paola Corona &Daniele Generali
Drug Design, Development and Therapy Volume 12, 2018 - Issue
Abemaciclib is the latest CDK4/6 inhibitor approved by the US Food and Drug Administration (FDA) in view of the results of the MONARCH 1 and 2 trials. Further trials are ongoing as other important questions await response.
1231929-97-7 Process route
-
-
6-(3-N,N-dimethylamino-2-fluoro-2-acrylketone-1-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzimidazole
-
![N-[5-(4-ethylpiperazine-1-yl-methyl)pyridine-2-yl]guanidine nitrate](/upload/2024/1/4bb0ed5c-d10c-448c-b9ad-6a095b5857b4.png)
-
N-[5-(4-ethylpiperazine-1-yl-methyl)pyridine-2-yl]guanidine nitrate
-
- 1231929-97-7
N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)-2-pyrimidinamine
| Conditions | Yield |
|---|---|
|
N-[5-(4-ethylpiperazine-1-yl-methyl)pyridine-2-yl]guanidine nitrate; With sulfuric acid; sodium methylate; In methanol; N,N-dimethyl-formamide; at 30 - 35 ℃; for 2h;
6-(3-N,N-dimethylamino-2-fluoro-2-acrylketone-1-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzimidazole; at 80 - 85 ℃; for 7h;
|
90.8% |
|
With sodium hydroxide; In butan-1-ol; at 90 - 100 ℃; Inert atmosphere;
|
73.1% |
-
- 5308-25-8
4-ethylpiperazine
-
![6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)nicotinaldehyde](/upload/2024/1/a142c691-aa44-49bc-8526-28af530926de.png)
-
6-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-yl)amino)nicotinaldehyde
-
- 1231929-97-7
N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)-2-pyrimidinamine
| Conditions | Yield |
|---|---|
|
With formic acid; trimethyl orthoformate; In acetonitrile; at 80 ℃; for 16h; Reagent/catalyst; Sealed tube;
|
74% |
1231929-97-7 Upstream products
-
1180132-17-5
5-((4-ethylpiperazin-1-yl)methyl)-6-methylpyridin-2-amine
-
1231930-42-9
6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
-
1231930-37-2
4-fluoro-1-isopropyl-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-benzo[d]imidazole
-
5308-25-8
4-ethylpiperazine
1231929-97-7 Downstream products
-
1231930-82-7
abemaciclib
-
1231930-82-7
LY2835219
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
FucoidanCAS：9072-19-9
-
RucaparibCAS：283173-50-2
